Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson’s Disease

Overview

This study is a non-interventional post-marketing observational study (PMOS) of participants with advanced Parkinson's disease (PD) treated with Duodopa/Duopa in a routine clinical setting. Effectiveness of treatment will be collected with physician and participant/caregiver health outcomes beginning with PMOS enrollment (baseline visit), at the start of Duodopa/Duopa treatment via percutaneous endoscopic gastrostomy-with jejunal extension (PEG-J), at regularly scheduled visits closest to Months 3 and 6, and every 6 months thereafter up to 36 months. An additional cohort of participants will be enrolled who in addition will be evaluated with a wearable device.

Full Title of Study: “DUOdopa/Duopa in Patients With Advanced Parkinson’s Disease (PD) – a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 27, 2021

Arms, Groups and Cohorts

  • Arm A: Participants with Advanced Parkinson’s Disease
    • Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries.
  • Arm B: Participants with Advanced Parkinson’s Disease
    • Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries. Participants will be evaluated with a wearable device

Clinical Trial Outcome Measures

Primary Measures

  • Change in the number of hours spent in OFF time in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment on OFF time measured by the change (from baseline to 36 months) in the number of hours spent in OFF time as reported by the participant for the day prior to the clinical visit.
  • Change in Duration of OFF time (hours/day) in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 6 months) in OFF time duration as measured by UPDRS Part IV (Motor Symptoms), item 39.
  • Change in Duration of OFF time (hours/day) in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 6 months) in OFF time duration as reported by participant with PD Diary both per full 24 hours and for the time period of 09:00 – 18:00
  • Duration of bradykinesia score above target in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 6 months) in duration of bradykinesia score above target between 09:00 – 18:00 and for the full 24 hours per day (measured by Parkinson’s KinetiGraph ( PKG))
  • Average bradykinesia score in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 6 months) in average bradykinesia score (measured by PKG)

Secondary Measures

  • Change in Disease-Specific Caregiver Burden in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in disease-specific caregiver burden as measured by the Modified Caregiver Strain Index (MCSI) for PD with a total score range from 0 to 26.
  • Change in the Duration of Dyskinesia in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in duration of dyskinesia as reported by the patient for the day prior to the clinical visit
  • Change in Disease-Specific Sleep Quality in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in disease-specific sleep quality as measured by Parkinson’s Disease Sleep Scale-2 (PDSS-2) with a total score range from 0 to 60.
  • Change in Tremor Severity in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in tremor severity as measured by UPDRS Part III, item 20 (Tremor at Rest) with a total score range of 0 to 20.
  • Change in Motor Function in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in motor function as measured by UPDRS, Part III (Motor Examination) with a total score range of 0 to 108.
  • Change in Generic Quality of Life in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in generic quality of life as measured by EuroQoL-5 Dimensions Quality of Life Questionnaire (EQ-5D). This assessment contains a health state descriptive part with five items scored from 1 to 3.
  • Change in Dyskinesia Severity in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in dyskinesia severity as measured by Unified Dyskinesia Rating Scale (UDysRS) with a total score range from 0 to 104.
  • Change in Overall Clinical Impression of Disease Severity in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in overall clinical impression of disease severity as measured by Clinical Impression of Severity Index for Parkinson’s Disease (CISI-PD) obtained by adding four domain scores with a total score range from 0 to 24.
  • Change in Disease-Specific Quality of Life in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in disease-specific quality of life (QoL) as measured by Parkinson’s Disease Questionnaire 8 (PDQ-8) summary index range from 0 to 100.
  • Change in OFF Time Duration in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in OFF time duration as measured by UPDRS Part IV (Motor Fluctuations), item 39, with a total score range of 0 to 4.
  • Change in Non-Motor Symptoms in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in non-motor symptoms as measured by Non-Motor Symptoms Scale (NMSS) with a total score range from 0 to 360.
  • Change in Healthcare Resource Utilization in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in healthcare resource utilization as measured by the Healthcare Resource Utilization Questionnaire (HCRU).
  • Change in Daytime Sleepiness in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in daytime sleepiness as measured by Epworth Sleepiness Scale (ESS) with a total score range from 0 to 24.
  • Change in Activities of Daily Living in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in Activities of Daily Living as measured by Unified Parkinson’s Disease Rating Scale (UPDRS) Part II (Activity of Daily Living) with a total score range of 0 to 52.
  • Change in Complications of Therapy in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the effectiveness of Duodopa/Duopa treatment measured by the change (from baseline to 36 months) in Complications of Therapy (dyskinesia duration, disability, pain and early morning dystonia) as measured by UPDRS Part IV (Complications of Therapy), items 32 (individual score 0 to 4), 33 (individual score 0 to 4), 34 (individual score 0 to 4), 35 (individual score 0 to 1) and total score range of 0 to 13.
  • Correlation of non-motor and motor improvements with Quality of Life improvements in Arm A
    • Time Frame: Baseline visit (Enrollment) to month 36
    • Assess the correlation of non-motor and motor improvements with the improvement in the Quality of Life (QOL).
  • Correlation between duration of OFF time measured by UPDRS IV and duration of bradykinesia score above target in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Assess the correlation between duration of OFF time measured by UPDRS IV item 39 and duration of bradykinesia score above target between 09:00 – 18:00 and for the full 24 hours per day measured by PKG
  • Correlation between duration of OFF time measured by patient with PD Diary and average bradykinesia score in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Assess the correlation between duration of OFF time measured by patient with PD Diary both per full 24 hours and for the time period of 09:00 – 18:00 and average bradykinesia score measured by PKG
  • Correlation between duration of bradykinesia score above target and average bradykinesia score in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Assess the correlation between duration of bradykinesia score above target between 09:00 – 18:00 and for the full 24 hours per day measured by PKG and average bradykinesia score measured by PKG
  • Correlation between duration of OFF time measured by patient with PD Diary and duration of bradykinesia score above target in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Assess the correlation between duration of OFF time measured by patient with PD Diary both per full 24 hours and for the time period of 09:00 – 18:00 and duration of bradykinesia score above target between 09:00 – 18:00 and for the full 24 hours per day measured by PKG
  • Correlation between duration of OFF time measured by UPDRS IV and average bradykinesia score in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Assess the correlation between duration of OFF time measured by UPDRS IV item 39 and average bradykinesia score measured by PKG
  • Correlation between duration of dyskinesia and Unified Dyskinesia Rating Scale (UDysRS) in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Pairwise correlation between duration of dyskinesia both per full 24 hours and 09:00 – 18:00 (based on UPDRS IV, PD diary and dyskinesia score measured by PKG) and UDysRS will be evaluated
  • Severity of dyskinesia in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Severity of dyskinesia (item 33 score of UPDRS IV, UDysRS total score or the PKG-based dyskinesia score and the pairwise correlation between these will be evaluated
  • Motor symptoms in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Motor symptoms measured by UPDRS III in ON state and correlation with PKG-based bradykinesia score will be evaluated
  • Severity of tremor in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Severity of tremor measured by item 20 of UPDRS III in ON state and PKG-based tremor score and correlation between both will be evaluated
  • Activities of Daily Living (ADL) in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • ADL measured by UPDRS II in ON state and correlation with and PKG-based fluctuation/dyskinesia score and bradykinesia score will be evaluated
  • Sleep in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Sleep as measured by PDSS-2, sleep/fatigue subdomain of NMSS, duration of sleep based on PD Diary or PKG-based night-time total sleep and pairwise correlation between these will be evaluated
  • Daytime sleepiness in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • Daytime sleepiness as measured by PKG-based percent of time asleep in the day time and the Epworth Sleepiness Scale and the correlation between these will be evaluated
  • Quality of Life (QoL) in Arm B
    • Time Frame: Baseline visit (Enrollment) to month 6
    • QoL as measured by PDQ-8 and the correlation with PKG-based fluctuation/dyskinesia and bradykinesia scores will be evaluated

Participating in This Clinical Trial

Inclusion Criteria

  • Eligibility for Duodopa/Duopa therapy in accordance with the approved local Duodopa/Duopa label in the participating country.
  • Duodopa/Duopa na├»ve participants
  • Decision to treat with Duodopa/Duopa made by the physician prior to any decision to approach the participant to participate in this study
  • Prior to any study-related procedures being performed, the participant, or legal authorized representative (LAR) has voluntarily signed an Authorization for Use/Disclosure of Data (AUDD)/informed consent form (ICF) according to national regulations after the study has been explained and the subject has had the opportunity to have questions answered.
  • For Arm B: Participant and caregiver must be motivated to use the PKG, understand the instructions and be able to handle the device.
  • For Arm B: participant must demonstrate at least 75% concordance with the investigator's or qualified designee's assessment of symptoms on the Parkinson's disease diary following training at enrollment visit 1/V1 with concordance on at least 1 time interval of "Off", concordance on at least 1 time interval of "ON regardless of dyskinesia" and at least 1 time interval of "ON with dyskinesia" irrespective of whether the dyskinesia are troublesome or not troublesome.

Exclusion Criteria

  • Any condition included in the contraindications section of the approved local Duodopa/Duopa label in the participating country.
  • Participants who have had previous surgery for PD including, but not limited to deep brain stimulation (DBS) or cell transplantation (this criterion removed for US sites for Arm A).
  • Participants currently in treatment with continuous apomorphine infusion. In case of a previous treatment with continuous subcutaneous apomorphine infusion, there must be at least 4 weeks between discontinuation of this treatment and inclusion into this study.
  • Mini-Mental State Examination (MMSE) score <24
  • Participation in a concurrent interventional clinical trial.
  • Lack of motivation or insufficient language skills to complete the study questionnaires

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AbbVie
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • AbbVie Inc., Study Director, AbbVie
  • Overall Contact(s)
    • Debra Cardoni, +18479389182, debbie.cardoni@abbvie.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.